325 related articles for article (PubMed ID: 21951990)
1. Improving treatment adherence in patients with schizophrenia.
Kane JM
J Clin Psychiatry; 2011 Sep; 72(9):e28. PubMed ID: 21951990
[TBL] [Abstract][Full Text] [Related]
2. Treatment adherence in schizophrenia and schizoaffective disorder.
Goff DC; Hill M; Freudenreich O
J Clin Psychiatry; 2011 Apr; 72(4):e13. PubMed ID: 21527119
[TBL] [Abstract][Full Text] [Related]
3. Review of treatments that can ameliorate nonadherence in patients with schizophrenia.
Kane JM
J Clin Psychiatry; 2006; 67 Suppl 5():9-14. PubMed ID: 16822091
[TBL] [Abstract][Full Text] [Related]
4. Long-acting injectable antipsychotics in the treatment of schizophrenia: their role in relapse prevention.
Agid O; Foussias G; Remington G
Expert Opin Pharmacother; 2010 Oct; 11(14):2301-17. PubMed ID: 20586707
[TBL] [Abstract][Full Text] [Related]
5. A randomized controlled trial of long-acting injectable risperidone vs continuation on oral atypical antipsychotics for first-episode schizophrenia patients: initial adherence outcome.
Weiden PJ; Schooler NR; Weedon JC; Elmouchtari A; Sunakawa A; Goldfinger SM
J Clin Psychiatry; 2009 Oct; 70(10):1397-406. PubMed ID: 19906343
[TBL] [Abstract][Full Text] [Related]
6. Relapse and therapeutic interventions in a 1-year observational cohort study of nonadherent outpatients with schizophrenia.
Ciudad A; San L; Bernardo M; Olivares JM; Polavieja P; Valladares A; Gilaberte I
Prog Neuropsychopharmacol Biol Psychiatry; 2012 Mar; 36(2):245-50. PubMed ID: 22056291
[TBL] [Abstract][Full Text] [Related]
7. Optimizing outcomes in schizophrenia: long-acting depots and long-term treatment.
Morrissette DA; Stahl SM
CNS Spectr; 2012 Nov; 17 Suppl 1():10-21. PubMed ID: 23462201
[TBL] [Abstract][Full Text] [Related]
8. Substance abuse and the management of medication nonadherence in schizophrenia.
Wilk J; Marcus SC; West J; Countis L; Hall R; Regier DA; Olfson M
J Nerv Ment Dis; 2006 Jun; 194(6):454-7. PubMed ID: 16772865
[TBL] [Abstract][Full Text] [Related]
9. [Is our clinical practice of antipsychotic relapse prevention in schizophrenia really evidence-based].
Schanda H; Stompe T
Neuropsychiatr; 2010; 24(1):14-26. PubMed ID: 20146916
[TBL] [Abstract][Full Text] [Related]
10. [Psychopharmocotherapy of schizophrenia in forensic and general psychiatry].
Stompe T; Schanda H
Neuropsychiatr; 2011; 25(2):75-84. PubMed ID: 21672506
[TBL] [Abstract][Full Text] [Related]
11. Overview of partial compliance.
Marder SR
J Clin Psychiatry; 2003; 64 Suppl 16():3-9. PubMed ID: 14680412
[TBL] [Abstract][Full Text] [Related]
12. Assessment of clinician awareness of nonadherence using a new structured rating scale.
Clayton CD; Veach J; Macfadden W; Haskins J; Docherty JP; Lindenmayer JP
J Psychiatr Pract; 2010 May; 16(3):164-9. PubMed ID: 20485104
[TBL] [Abstract][Full Text] [Related]
13. Oral antipsychotic update: a brief review of new and investigational agents for the treatment of schizophrenia.
Citrome L
CNS Spectr; 2012 Nov; 17 Suppl 1():1-9. PubMed ID: 23448847
[TBL] [Abstract][Full Text] [Related]
14. How do socio-demographic and clinical factors interact with adherence attitude profiles in schizophrenia? A cluster-analytical approach.
Beck EM; Cavelti M; Wirtz M; Kossowsky J; Vauth R
Psychiatry Res; 2011 May; 187(1-2):55-61. PubMed ID: 21074860
[TBL] [Abstract][Full Text] [Related]
15. Recognition of patients who would benefit from LAI antipsychotic treatment: how to assess adherence.
Correll CU
J Clin Psychiatry; 2014 Nov; 75(11):e29. PubMed ID: 25470105
[TBL] [Abstract][Full Text] [Related]
16. Strategies for improving compliance in treatment of schizophrenia by using a long-acting formulation of an antipsychotic: clinical studies.
Kane JM
J Clin Psychiatry; 2003; 64 Suppl 16():34-40. PubMed ID: 14680417
[TBL] [Abstract][Full Text] [Related]
17. [Therapeutic alliance, a stake in schizophrenia].
Charpentier A; Goudemand M; Thomas P
Encephale; 2009 Feb; 35(1):80-9. PubMed ID: 19250998
[TBL] [Abstract][Full Text] [Related]
18. Relapse and rehospitalization: comparing oral and depot antipsychotics.
Schooler NR
J Clin Psychiatry; 2003; 64 Suppl 16():14-7. PubMed ID: 14680414
[TBL] [Abstract][Full Text] [Related]
19. Review and analysis of hospitalization costs associated with antipsychotic nonadherence in the treatment of schizophrenia in the United States.
Sun SX; Liu GG; Christensen DB; Fu AZ
Curr Med Res Opin; 2007 Oct; 23(10):2305-12. PubMed ID: 17697454
[TBL] [Abstract][Full Text] [Related]
20. Monitoring treatment and managing adherence in schizophrenia.
Marder SR
J Clin Psychiatry; 2013 Oct; 74(10):e21. PubMed ID: 24229761
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]